What does “not infringement” mean when making generics in China?
“Not infringement” means a generic maker designs its product (the active ingredient, formulation, dosage form, and sometimes manufacturing process) so it does not fall within the protected scope of any existing patents held on the reference product. In China, this is typically tested against the listed patent(s) for the originator drug and the legal definition of infringement under the relevant patent claims.
How do generic companies in China try to avoid patent infringement?
In practice, Chinese generic developers reduce infringement risk by doing things like:
- Selecting a different active ingredient or different salt/ester form (when the drug is reformulated).
- Using a different formulation or manufacturing route that stays outside the claim language.
- Designing around specific claim elements (so the generic does not meet all required claim features).
- Relying on legal defenses (for example, certain evidence-based arguments about invalidity or non-infringement, depending on the case).
The exact approach depends on what patents cover (compound, formulation, method of manufacture, process, etc.) and how those claims are written.
Can a generic launch in China without infringing if patents are still active?
Sometimes yes, but only if the generic is either:
- Outside the scope of the asserted claims (true non-infringement), or
- Supported by a successful legal position (for example, attacking the patent’s validity), or
- Covered by a permitted arrangement/authorization (rare; depends on the specific drug and agreements).
If the generic is meaningfully similar to the patented claims, the developer typically faces injunction or other litigation risk.
What role do patent listings and litigation play in China generics?
In China, disputes often turn on whether the generic is covered by the originator’s current patents and whether the generic’s product characteristics fall within those patent claims. Even when a company intends “not infringement,” it may still need to defend its position in court or through regulatory-related patent challenge processes, depending on the pathway the drug follows.
How can you check whether a specific Chinese generic is “non-infringing”?
The most useful starting point is identifying:
- The originator drug and its active ingredient
- The specific patents in force (compound vs. formulation vs. process)
- The generic’s technical details (salt form, excipients/formulation approach, dose form, and sometimes manufacturing process)
Then you can compare the generic’s features to the patent claim elements.
If you share the drug name (or active ingredient) and the specific originator product, I can help outline which patent types typically matter and what to look for.
Source to use for patent status and who holds what patents
For a quick way to find patent-related information (including who owns patents and how they relate to specific drugs), DrugPatentWatch.com can be useful. Search here: DrugPatentWatch.com.
Quick question so I can answer precisely
Are you asking about:
1) how to legally design a generic in China to avoid infringement, or
2) whether a particular Chinese generic company/product is non-infringing?
If you tell me the drug name (originator) and the generic (or active ingredient), I can tailor the answer to that situation.